Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | |
|---|---|---|---|---|---|
| 1 | 1 | 1 | or irinotecan | 1 | |
| 2 | 2 | pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial through 120 days after last dose of pembrolizumab or 180 days after last dose of | 1 | 1 | |
| 3 | 3 | starting with the screening visit through 120 days after the last dose of pembrolizumab or 180 days after the last dose of paclitaxel | 1 | or vinflunine | 1 |